BOTOX® Cosmetic (onabotulinumtoxinA) is now FDA-approved for treating moderate to severe vertical neck bands (platysma bands).

AstraZeneca submitted a market application for the injectable drug Tremelimumab.

LaNova Medicines has begun a Phase 1 clinical trial for its bispecific antibody LM-299 targeting PD-1 and VEGF, and has finalized a Series C1 funding round of $42 million.

Nurix Therapeutics unveiled promising data from its Phase 1a/1b clinical trial of NX-5948 at the 12th International Workshop on Waldenstrom's Macroglobulinemia.

Genentech's Vabysmo enhanced vision in underserved groups with Diabetic Macular Edema (DME) in a groundbreaking study.

Astellas’ VYLOY™ (zolbetuximab-clzb) has received U.S. FDA approval for treating advanced gastric and GEJ cancers.

Tenaya Therapeutics provides updates on its TN-201 gene therapy project targeting MYBPC3-related HCM.

ARTHEx Biotech has initiated dosing for the first patient in the Phase I-IIa trial of ArthemiR™ for Myotonic Dystrophy Type 1 (DM1).

In the development of antibody-drug conjugates (ADCs), selecting an appropriate linker is a critical factor that determines the efficacy and safety of the final product.

BioAegis Therapeutics has initiated its Phase 2 clinical trial for Gelsolin, an immune modulator, by enrolling its first patient to address Acute Respiratory Distress Syndrome (ARDS).

Poseida Therapeutics focuses on developing unique non-viral therapies for individuals suffering from cancer, autoimmune disorders, and rare diseases.

The U.S. FDA has authorized VYALEV™ (foscarbidopa and foslevodopa) for adults with advanced Parkinson’s disease.